Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability.

Development 97

Development Drugs Immune Response Manufacturing 97

pharmaphorum

JULY 22, 2021

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells’ natural protein-denaturing machinery to remove rogue proteins associated with disease. billion in backloaded milestone payments.

Protein 116

Protein Hormones Bioavailability Drugs 116

Camargo

JULY 8, 2021

At Camargo, we have worked with hundreds of investigators who have found new targets for established drugs. It is exciting to find new uses of drugs with known safety because these drugs can reach new groups of patients in a relatively short timeframe. ” .

Development 130

Development Bioequivalency Gene Expression Drugs 130

Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Pediatric Research Equity Act (PREA) Requirements.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

XTalks

JUNE 27, 2024

Oral drugs are the most convenient and sought-after form of drug administration. This means they must be digested completely so the active pharmaceutical ingredients (APIs) in the drug can be absorbed by the body. Therefore, techniques and technologies that promote drug solubility and bioavailability are in high demand.

Bioavailability 59

Bioavailability Manufacturing Drugs Development 59

Pharmaceutical Technology

JANUARY 25, 2023

They provide a higher ability to regulate protein levels and can affect the non-enzymatic function of the protein while also providing an alternative to targeting drug-resistant proteins for overcoming tumour drug resistance.

Protein 130

Protein Bioavailability Development Scientist 130

Pharmaceutical Technology

FEBRUARY 13, 2023

However, there is a high level of attrition during the pharmaceutical research and development process, which is an indicator of the vast number of potential drug substances considered for progression. With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage?

Development 130

Development In-Vivo Drugs Clinical Trials 130

XTalks

OCTOBER 2, 2024

Recognized with Fast Track designation from the US Food and Drug Administration (FDA), fasedienol could become a much-needed treatment option for the 30 million Americans affected by SAD. If successful, this trial could pave the way for a New Drug Application (NDA) submission.

Research 52

Research Bioavailability Trials Hormones 52

Roots Analysis

MAY 21, 2024

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Roots Analysis

MARCH 1, 2022

Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Bioavailability 52

Roots Analysis

MARCH 2, 2022

However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs. Web: [link].

Protein 52

Protein Drugs Drug Delivery Drug Delivery Systems 52

The Pharma Data

JANUARY 7, 2021

. The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. The number of biopharmaceutical products show a considerable growth accounting for nearly a quarter of the new molecular entities approved in 2017.

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

The Pharma Data

APRIL 7, 2023

CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. That is why, in recent years, cyclic peptides have become a very active research area.

Drugs 40

Drugs Protein Bioavailability Research 40

Roots Analysis

FEBRUARY 20, 2022

Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Our Social Media Platform. Web: [link]. LinkedIn: [link].

Contract Manufacturing 52

Contract Manufacturing Bioavailability Manufacturing Drug Delivery Systems 52

Roots Analysis

OCTOBER 2, 2023

Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Development 40

The Pharma Data

JANUARY 27, 2021

Construction of commercial drug manufacturing facility in Germany. Psychedelic transdermal and sublingual drug formulation development. Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental health conditions.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. Session Category: Clinical Research (Excluding Trials). Portfolio Highlights.

Research 52

Research Clinical Trials Clinical Trials Trials 52

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013.

Trials 83

Trials Drug Delivery Drugs Gene 83

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. In August 2016, nintedanib gained Orphan drug Designation from European Commission to treat systemic sclerosis. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History. In March 2020, The U.S.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

XTalks

FEBRUARY 3, 2023

The US Food and Drug Administration (FDA) has approved the first and only oral drug for the treatment of advanced or metastatic breast cancer in postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) ESR1 mutations. months on elacestrant compared with 1.9

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

Delveinsight

AUGUST 25, 2020

The drug, Spartalizumab, is an experimental monoclonal antibody designed as immunotherapy to target the human programmed death-1 (PD-1) receptor. The drug uses an optimized salt form of niclosamide, which is a safe oral drug and is in use for decades as an anthelmintic drug.

Trials 52

Trials Bioavailability Drugs Protein 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. The company employs 8 people and is supported by BPI France, the National Research Agency and Eurasanté.

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

DECEMBER 1, 2020

Genesis is progressing both an internal drug pipeline, as well as select external partnerships, to create transformative therapies for patients. We are united in our view that drug discovery and development must raise its success rate. Most recently, Genesis announced a multi-target partnership with Genentech. Feinberg, Ph.D.,

Development 40

Development Drugs Engineer FDA Approval 40

The Pharma Data

NOVEMBER 11, 2020

Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. While SLV213 can be dosed orally or intravenously, Selva is first advancing it as an oral drug candidate for COVID-19. About SLV213.

Protein 52

Protein Bioavailability Development Drugs 52

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company NRG Therapeutics Ltd.,

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Delveinsight

FEBRUARY 16, 2021

Chemotherapy drugs while killing cancer cells also damages normal tissues. The drug is the first and only therapy that is developed and approved to protect bone marrow (myeloprotection), which is injected prior to treatment with chemotherapy, asserts the US oncology drug developer, G1.

Marketing 52

Marketing Protein Bioavailability Drugs 52

The Pharma Data

MARCH 8, 2021

Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related. This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo. “We

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Delveinsight

JANUARY 7, 2021

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs. Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The newer side of the pipeline points targeted oncology drugs. Terns raises USD 87 Million for NASH drugs. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

JULY 12, 2021

“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

XTalks

MAY 23, 2024

Drugs such as pembrolizumab (Merck’s Keytruda) and nivolumab (Bristol Myers Squibb’s Opdivo) have revolutionized the treatment options for skin cancer. Ongoing research on molecular diagnostics and AI-powered diagnostic tools has helped enhance the early detection and treatment of skin cancer, promising improved patient outcomes.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

Roots Analysis

SEPTEMBER 1, 2023

Real World Data and Blue Ocean Strategy Real-world data is particularly useful for researchers, as it provides valuable insights from patient data and knowledge that can impact many decision-making processes. New Drug Formulations as a Blue Ocean Strategy New drug formulations can help improve patient adherence and reduce side effects.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

Roots Analysis

MARCH 13, 2022

Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. Biopharmaceutical excipients can range from simple inert entities to complex compounds.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

The Pharma Data

OCTOBER 15, 2020

In addition, acquired drug resistance has been reported in patients after treatment with approved TRK protein inhibitors. Hence, Cullgen’s TRK degraders could offer patients a new therapeutic approach to treat TRK-mediated cancer diseases with reduced drug resistance. “We

Protein 40

Protein Medicine Bioavailability Development 40

XTalks

SEPTEMBER 24, 2024

With no cure currently available, managing symptoms and improving the quality of life for patients remain critical goals for medical research and treatment. This magazine immerses you in a world where industry leaders, patient advocates and top researchers converge to provide the most insightful perspectives on clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

The Pharma Data

DECEMBER 9, 2020

Spun out of CEO and co-founder Evan Feinberg’s breakthrough artificial Intelligence (AI) research at Stanford University’s Pande Lab , Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs. Genesis Therapeutics.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Delveinsight

SEPTEMBER 8, 2021

The exact cause of SLE is unknown; however, factors such as sunlight and drugs may precipitate the condition, and many studies have revealed a complex genetic basis. The first line of therapy/agents recommended for the Systemic Lupus Erythematosus treatment includes Nonsteroidal anti-inflammatory drugs (NSAIDs) (Naproxen, Celecoxib, etc.),

Marketing 52

Marketing Sales FDA Approval Antibody 52